DBV Technologies (NASDAQ:DBVT) Stock Price Up 7.2% – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price was up 7.2% during mid-day trading on Friday . The stock traded as high as $17.00 and last traded at $17.20. Approximately 6,160 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 289,443 shares. The stock had previously closed at $16.04.

Analysts Set New Price Targets

DBVT has been the subject of several research reports. Guggenheim restated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th. Citizens Jmp boosted their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, May 1st. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Finally, Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Trading Up 5.0%

The business’s fifty day simple moving average is $19.48 and its 200-day simple moving average is $19.65. The firm has a market cap of $1.03 billion, a P/E ratio of -3.90 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. Analysts anticipate that DBV Technologies S.A. will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in DBVT. Artisan Partners Limited Partnership increased its position in DBV Technologies by 6,273.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the period. Vivo Capital LLC boosted its holdings in shares of DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares during the last quarter. Siren L.L.C. acquired a new position in shares of DBV Technologies in the 4th quarter valued at $35,606,000. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies during the second quarter worth $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies during the second quarter worth $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.